339 related articles for article (PubMed ID: 18226617)
1. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion.
Stepan H; Geipel A; Schwarz F; Krämer T; Wessel N; Faber R
Am J Obstet Gynecol; 2008 Feb; 198(2):175.e1-6. PubMed ID: 18226617
[TBL] [Abstract][Full Text] [Related]
2. Relation between maternal angiogenic factors and utero-placental resistance in normal first- and second-trimester pregnancies.
Petzold K; Jank A; Faber R; Stepan H
Hypertens Pregnancy; 2011; 30(4):401-7. PubMed ID: 20726742
[TBL] [Abstract][Full Text] [Related]
3. First-trimester serum levels of soluble endoglin and soluble fms-like tyrosine kinase-1 as first-trimester markers for late-onset preeclampsia.
Baumann MU; Bersinger NA; Mohaupt MG; Raio L; Gerber S; Surbek DV
Am J Obstet Gynecol; 2008 Sep; 199(3):266.e1-6. PubMed ID: 18771978
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic biomarkers for prediction of early preeclampsia onset in high-risk women.
Moore Simas TA; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Maynard SE
J Matern Fetal Neonatal Med; 2014 Jul; 27(10):1038-48. PubMed ID: 24066977
[TBL] [Abstract][Full Text] [Related]
5. Angiogenic factors and uterine Doppler velocimetry in early- and late-onset preeclampsia.
Tobinaga CM; Torloni MR; Gueuvoghlanian-Silva BY; Pendeloski KP; Akita PA; Sass N; Daher S
Acta Obstet Gynecol Scand; 2014 May; 93(5):469-76. PubMed ID: 24580069
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion.
Stepan H; Unversucht A; Wessel N; Faber R
Hypertension; 2007 Apr; 49(4):818-24. PubMed ID: 17261644
[TBL] [Abstract][Full Text] [Related]
7. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
8. Soluble endoglin for the prediction of preeclampsia in a high risk cohort.
Maynard SE; Moore Simas TA; Bur L; Crawford SL; Solitro MJ; Meyer BA
Hypertens Pregnancy; 2010; 29(3):330-41. PubMed ID: 20670156
[TBL] [Abstract][Full Text] [Related]
9. An analysis on the roles of angiogenesis-related factors including serum vitamin D, soluble endoglin (sEng), soluble fms-like tyrosine kinase 1 (sFlt1), and vascular endothelial growth factor (VEGF) in the diagnosis and severity of late-onset preeclampsia.
Cim N; Kurdoglu M; Ege S; Yoruk I; Yaman G; Yildizhan R
J Matern Fetal Neonatal Med; 2017 Jul; 30(13):1602-1607. PubMed ID: 27658884
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study.
Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE
Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463
[TBL] [Abstract][Full Text] [Related]
11. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset.
Hirashima C; Ohkuchi A; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Res; 2008 Aug; 31(8):1541-8. PubMed ID: 18971528
[TBL] [Abstract][Full Text] [Related]
12. [Angiogenic factors and their role in pathogenesis and prediction of preeclampsia].
Stepan H; Jank A
Z Geburtshilfe Neonatol; 2009 Jun; 213(3):101-5. PubMed ID: 19536710
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy.
Salahuddin S; Lee Y; Vadnais M; Sachs BP; Karumanchi SA; Lim KH
Am J Obstet Gynecol; 2007 Jul; 197(1):28.e1-6. PubMed ID: 17618745
[TBL] [Abstract][Full Text] [Related]
14. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia.
Kusanovic JP; Romero R; Chaiworapongsa T; Erez O; Mittal P; Vaisbuch E; Mazaki-Tovi S; Gotsch F; Edwin SS; Gomez R; Yeo L; Conde-Agudelo A; Hassan SS
J Matern Fetal Neonatal Med; 2009 Nov; 22(11):1021-38. PubMed ID: 19900040
[TBL] [Abstract][Full Text] [Related]
15. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia.
Rana S; Karumanchi SA; Levine RJ; Venkatesha S; Rauh-Hain JA; Tamez H; Thadhani R
Hypertension; 2007 Jul; 50(1):137-42. PubMed ID: 17515455
[TBL] [Abstract][Full Text] [Related]
16. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
Powers RW; Jeyabalan A; Clifton RG; Van Dorsten P; Hauth JC; Klebanoff MA; Lindheimer MD; Sibai B; Landon M; Miodovnik M;
PLoS One; 2010 Oct; 5(10):e13263. PubMed ID: 20948996
[TBL] [Abstract][Full Text] [Related]
17. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction.
Stepan H; Krämer T; Faber R
J Clin Endocrinol Metab; 2007 Jul; 92(7):2831-4. PubMed ID: 17426082
[TBL] [Abstract][Full Text] [Related]
18. Soluble endoglin as a second-trimester marker for preeclampsia.
Robinson CJ; Johnson DD
Am J Obstet Gynecol; 2007 Aug; 197(2):174.e1-5. PubMed ID: 17689640
[TBL] [Abstract][Full Text] [Related]
19. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.
Rana S; Cerdeira AS; Wenger J; Salahuddin S; Lim KH; Ralston SJ; Thadhani RI; Karumanchi SA
PLoS One; 2012; 7(10):e48259. PubMed ID: 23110221
[TBL] [Abstract][Full Text] [Related]
20. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
